In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]
The model, beginning in 2026 for Medicaid and 2027 for Medicare, is voluntary for drug manufacturers, state Medicaid programs, and Medicare Part D plans
HR 1.19, 95% CI 0.91.58), but not for the other DPP-4 inhibitors as in the TECOS study for sitagliptin (HR 1.00, 95% CI 0.831.20) or the CARMELINA study for linagliptin (HR 0.90, 95% CI 0.741.08) (57, 62, 64, 65, 68)
What makes Eden particularly well-suited for low-dose starters is its predictable pricing model
TrimRx sources compounded medications exclusively from FDA-registered 503B facilities
Unfortunately, despite significant advances in anti-glycemic therapies, macrovascular complications are still the most common cause of death in T2D patients [5]